Sonnet BioTherapeutics Holdings, Inc.
DelistedCIK 1106838fmd_1WTW4RTA59ZTBD7EWH7XKYX34YManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Oct 01, 2009 to Sep 30, 2025, 62 periods
Latest annual · FY2025
Millions- Total revenues
- 1
- Operating income
- (16)
- Net income
- (16)
Latest quarter · Q4 FY2025
Millions- Total revenues
- 0
- Operating income
- (5)
- Net income
- (6)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +41.9%
- Revenue, 5 yearsFY2020 to FY2025
- n/m
- Net income, 5 yearsFY2020 to FY2025
- n/m
Sonnet BioTherapeutics Holdings, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $1 million | $18,626 | +5,268.8% | 10-K 2025-12-16 · proof |
| Operating income | -$15.8 million | -$11.8 million | 10-K 2025-12-16 · proof | |
| Net income | -$16 million | -$7.4 million | 10-K 2025-12-16 · proof | |
| Cash from operating activities | -$12.8 million | -$8.6 million | 10-K 2025-12-16 · proof | |
| Total assets | $14.9 million | $2.8 million | +437.1% | 10-K 2025-12-16 · proof |
| Total liabilities | $4.1 million | $3.3 million | +25.8% | 10-K 2025-12-16 · proof |
| Cash and cash equivalents | $5.1 million | $149,456 | +3,325.9% | 10-K 2025-12-16 · proof |
- What was Sonnet BioTherapeutics Holdings, Inc.'s revenue in fiscal 2025?
- Sonnet BioTherapeutics Holdings, Inc. reported revenue of $1 million for fiscal 2025 (the year ended Sep 30, 2025), against $18,626 the year before (+5,268.8%). Source: the 10-K filed with the SEC on Dec 16, 2025. SEC
- What was Sonnet BioTherapeutics Holdings, Inc.'s operating income in fiscal 2025?
- Sonnet BioTherapeutics Holdings, Inc. reported operating income of -$15.8 million for fiscal 2025 (the year ended Sep 30, 2025), against -$11.8 million the year before. Source: the 10-K filed with the SEC on Dec 16, 2025. SEC
- What was Sonnet BioTherapeutics Holdings, Inc.'s net income in fiscal 2025?
- Sonnet BioTherapeutics Holdings, Inc. reported net income of -$16 million for fiscal 2025 (the year ended Sep 30, 2025), against -$7.4 million the year before. Source: the 10-K filed with the SEC on Dec 16, 2025. SEC
- What was Sonnet BioTherapeutics Holdings, Inc.'s cash from operating activities in fiscal 2025?
- Sonnet BioTherapeutics Holdings, Inc. reported cash from operating activities of -$12.8 million for fiscal 2025 (the year ended Sep 30, 2025), against -$8.6 million the year before. Source: the 10-K filed with the SEC on Dec 16, 2025. SEC
- What are Sonnet BioTherapeutics Holdings, Inc.'s total assets?
- As of Sep 30, 2025, Sonnet BioTherapeutics Holdings, Inc. reported total assets of $14.9 million, against $2.8 million a year earlier (+437.1%). Source: the 10-K filed with the SEC on Dec 16, 2025. SEC
- What are Sonnet BioTherapeutics Holdings, Inc.'s total liabilities?
- As of Sep 30, 2025, Sonnet BioTherapeutics Holdings, Inc. reported total liabilities of $4.1 million, against $3.3 million a year earlier (+25.8%). Source: the 10-K filed with the SEC on Dec 16, 2025. SEC
- What are Sonnet BioTherapeutics Holdings, Inc.'s cash and cash equivalents?
- As of Sep 30, 2025, Sonnet BioTherapeutics Holdings, Inc. reported cash and cash equivalents of $5.1 million, against $149,456 a year earlier (+3,325.9%). Source: the 10-K filed with the SEC on Dec 16, 2025. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1106838&period_type=annual&limit=5"Information only, not investment advice.